Sarepta Therapeutics, Inc. (SRPT)

$128.92

-4.85

(-3.63%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $126.84
    $134.55
    $128.92
    downward going graph

    1.61%

    Downside

    Day's Volatility :5.73%

    Upside

    4.18%

    downward going graph
  • $55.25
    $173.25
    $128.92
    downward going graph

    57.14%

    Downside

    52 Weeks Volatility :68.11%

    Upside

    25.59%

    downward going graph

Returns

PeriodSarepta Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
4.54%
5.1%
0.0%
6 Months
6.74%
4.9%
0.0%
1 Year
5.67%
16.6%
0.0%
3 Years
64.08%
13.2%
-22.3%

Highlights

Market Capitalization
12.8B
Book Value
$11.3
Earnings Per Share (EPS)
0.75
PE Ratio
178.36
PEG Ratio
159.25
Wall Street Target Price
188.73
Profit Margin
3.14%
Operating Margin TTM
-0.19%
Return On Assets TTM
0.73%
Return On Equity TTM
5.2%
Revenue TTM
1.5B
Revenue Per Share TTM
15.79
Quarterly Revenue Growth YOY
38.9%
Gross Profit TTM
-78.1M
EBITDA
77.8M
Diluted Eps TTM
0.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.59
EPS Estimate Next Year
11.23
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.99

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Sarepta Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
25
25
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 46.39%

Current $128.92
Target $188.73

Company Financials

FY18Y/Y Change
Revenue
301.0M
↑ 94.74%
Net Income
-361.9M
↑ 614.01%
Net Profit Margin
-120.22%
↓ 87.43%
FY19Y/Y Change
Revenue
380.8M
↑ 26.51%
Net Income
-715.1M
↑ 97.58%
Net Profit Margin
-187.77%
↓ 67.55%
FY20Y/Y Change
Revenue
540.1M
↑ 41.82%
Net Income
-554.1M
↓ 22.51%
Net Profit Margin
-102.6%
↑ 85.17%
FY21Y/Y Change
Revenue
701.9M
↑ 29.96%
Net Income
-418.8M
↓ 24.43%
Net Profit Margin
-59.66%
↑ 42.94%
FY22Y/Y Change
Revenue
933.0M
↑ 32.93%
Net Income
-703.5M
↑ 67.99%
Net Profit Margin
-75.4%
↓ 15.74%
FY23Y/Y Change
Revenue
1.2B
↑ 33.26%
Net Income
-536.0M
↓ 23.81%
Net Profit Margin
-43.11%
↑ 32.29%
Q1 FY23Q/Q Change
Revenue
253.5M
↓ 1.91%
Net Income
-516.8M
↑ 373.03%
Net Profit Margin
-203.85%
↓ 161.58%
Q2 FY23Q/Q Change
Revenue
261.2M
↑ 3.05%
Net Income
-23.9M
↓ 95.37%
Net Profit Margin
-9.16%
↑ 194.69%
Q3 FY23Q/Q Change
Revenue
331.8M
↑ 27.02%
Net Income
-40.9M
↑ 71.0%
Net Profit Margin
-12.34%
↓ 3.18%
Q4 FY23Q/Q Change
Revenue
396.8M
↑ 19.58%
Net Income
45.7M
↓ 211.53%
Net Profit Margin
11.51%
↑ 23.85%
Q1 FY24Q/Q Change
Revenue
413.5M
↑ 4.2%
Net Income
36.1M
↓ 20.89%
Net Profit Margin
8.74%
↓ 2.77%
Q2 FY24Q/Q Change
Revenue
362.9M
↓ 12.22%
Net Income
6.5M
↓ 82.11%
Net Profit Margin
1.78%
↓ 6.96%
FY18Y/Y Change
Total Assets
1.6B
↑ 25.54%
Total Liabilities
609.8M
↑ 17.55%
FY19Y/Y Change
Total Assets
1.8B
↑ 11.01%
Total Liabilities
1.0B
↑ 64.75%
FY20Y/Y Change
Total Assets
3.0B
↑ 63.74%
Total Liabilities
2.2B
↑ 121.27%
FY21Y/Y Change
Total Assets
3.1B
↑ 5.47%
Total Liabilities
2.2B
↓ 0.13%
FY22Y/Y Change
Total Assets
3.1B
↓ 0.62%
Total Liabilities
2.7B
↑ 23.58%
FY23Y/Y Change
Total Assets
3.3B
↑ 4.35%
Total Liabilities
2.4B
↓ 12.33%
Q1 FY23Q/Q Change
Total Assets
3.1B
↓ 2.19%
Total Liabilities
2.3B
↓ 14.45%
Q2 FY23Q/Q Change
Total Assets
3.1B
↑ 2.16%
Total Liabilities
2.4B
↑ 1.6%
Q3 FY23Q/Q Change
Total Assets
3.1B
↓ 0.52%
Total Liabilities
2.3B
↓ 1.64%
Q4 FY23Q/Q Change
Total Assets
3.3B
↑ 4.98%
Total Liabilities
2.4B
↑ 2.55%
Q1 FY24Q/Q Change
Total Assets
3.2B
↓ 1.23%
Total Liabilities
2.3B
↓ 5.91%
Q2 FY24Q/Q Change
Total Assets
3.4B
↑ 6.2%
Total Liabilities
2.3B
↑ 3.71%
FY18Y/Y Change
Operating Cash Flow
-388.7M
↑ 67.53%
Investing Cash Flow
-370.5M
↑ 107.19%
Financing Cash Flow
530.2M
↓ 40.3%
FY19Y/Y Change
Operating Cash Flow
-456.5M
↑ 17.45%
Investing Cash Flow
286.7M
↓ 177.39%
Financing Cash Flow
642.6M
↑ 21.2%
FY20Y/Y Change
Operating Cash Flow
107.5M
↓ 123.54%
Investing Cash Flow
-121.7M
↓ 142.45%
Financing Cash Flow
682.3M
↑ 6.19%
FY21Y/Y Change
Operating Cash Flow
-443.2M
↓ 512.38%
Investing Cash Flow
495.4M
↓ 507.01%
Financing Cash Flow
561.6M
↓ 17.7%
FY22Y/Y Change
Operating Cash Flow
-325.3M
↓ 26.59%
Investing Cash Flow
-1.0B
↓ 311.32%
Financing Cash Flow
232.5M
↓ 58.6%
Q1 FY23Q/Q Change
Operating Cash Flow
-209.4M
↑ 126.64%
Investing Cash Flow
12.5M
↑ 27.52%
Financing Cash Flow
101.8M
↑ 847.02%

Technicals Summary

Sell

Neutral

Buy

Sarepta Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
-7.95%
6.74%
5.67%
64.08%
48.8%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
178.36
178.36
159.25
1.59
0.05
0.01
NA
11.3
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Buy
$12.8B
48.8%
178.36
3.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Sarepta Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 413.46M → 362.93M (in $), with an average decrease of 12.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 45.65M → 6.46M (in $), with an average decrease of 51.5% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 31.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 5.1%

Institutional Holdings

  • BlackRock Inc

    10.83%

  • Vanguard Group Inc

    9.47%

  • Capital Research & Mgmt Co - Division 3

    4.53%

  • HHG PLC

    4.00%

  • venBio Select Advisor LLC

    3.15%

  • Farallon Capital Management, L.L.C.

    2.41%

Company Information

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.

Organization
Sarepta Therapeutics, Inc.
Employees
1314
CEO
Mr. Douglas S. Ingram Esq.
Industry
Health Technology

Discover More

FAQs